2. Signaling Pathways
  3. Protein Tyrosine Kinase/RTK
  4. Bcr-Abl
  5. Bcr-Abl Isoform
  6. Bcr-Abl Inhibitor

Bcr-Abl Inhibitor

Bcr-Abl Inhibitors (62):

Cat. No. Product Name Effect Purity
  • HY-10181
    Dasatinib
    		Inhibitor 99.85%
    Dasatinib (BMS-354825) is a highly potent, ATP competitive, orally active dual Src/Bcr-Abl inhibitor with potent antitumor activity.
  • HY-15463
    Imatinib
    		Inhibitor 99.95%
    Imatinib (STI571) is an orally bioavailable tyrosine kinases inhibitor that selectively inhibits BCR/ABL, v-Abl, PDGFR and c-kit kinase activity.
  • HY-10159
    Nilotinib
    		Inhibitor 99.96%
    Nilotinib is an orally available Bcr-Abl tyrosine kinase inhibitor with antineoplastic activity.
  • HY-10158
    Bosutinib
    		Inhibitor 99.96%
    Bosutinib is an orally active Src/Abl tyrosine kinase inhibitor with IC50 of 1.2 nM and 1 nM, respectively.
  • HY-104010
    Asciminib
    		Inhibitor 99.88%
    Asciminib (ABL001) is a potent and selective allosteric BCR-ABL1 inhibitor, which inhibits Ba/F3 cells grown with an IC50 of 0.25 nM.
  • HY-10181A
    Dasatinib hydrochloride
    		Inhibitor 98.86%
    Dasatinib (BMS-354825) hydrochloride is a highly potent, ATP competitive, orally active dual Src/Bcr-Abl inhibitor with potent antitumor activity.
  • HY-101489A
    GZD856 formic
    		Inhibitor 98.06%
    GZD856 formic is a potent and orally active PDGFRα/β inhibitor, with IC50s of 68.6 and 136.6 nM, respectively.
  • HY-50946
    Imatinib Mesylate
    		Inhibitor 99.98%
    Imatinib Mesylate (STI571 Mesylate) is a tyrosine kinases inhibitor that inhibits c-Kit, Bcr-Abl, and PDGFR (IC50=100 nM) tyrosine kinases.
  • HY-13024
    Rebastinib
    		Inhibitor 99.91%
    Rebastinib (DCC-2036) is an orally active, non-ATP-competitive Bcr-Abl inhibitor for Abl1WT and Abl1T315I with IC50s of 0.8 nM and 4 nM, respectively.
  • HY-15666
    Olverembatinib
    		Inhibitor 99.78%
    Olverembatinib (GZD824) is a potent and orally active pan-Bcr-Abl inhibitor.
  • HY-13264
    Degrasyn
    		Inhibitor 99.70%
    Degrasyn (WP1130) is a cell-permeable deubiquitinase (DUB) inhibitor, directly inhibiting DUB activity of USP9x, USP5, USP14, and UCH37.
  • HY-50868
    Bafetinib
    		Inhibitor 99.76%
    Bafetinib is a potent and orally active Lyn/Bcr-Abl tyrosine kinase inhibitor.
  • HY-10159A
    Nilotinib monohydrochloride monohydrate
    		Inhibitor 99.89%
    Nilotinib monohydrochloride monohydrate is a second generation tyrosine kinase inhibitor (TKI), is significantly potent against BCR-ABL, and is active against many BCR-ABL mutants.
  • HY-10395
    PD173955
    		Inhibitor 99.12%
    PD173955 is src family-selective tyrosine kinase inhibitor with IC50 of ~22 nM for for Src, Yes and Abl kinase.
  • HY-15002
    AST 487
    		Inhibitor 99.42%
    AST 487 is a RET kinase inhibitor with IC50 of 880 nM, inhibits RET autophosphorylation and activation of downstream effectors, also inhibits Flt-3 with IC50 of 520 nM.
  • HY-13904
    Flumatinib
    		Inhibitor 99.94%
    Flumatinib (HHGV678) is an orally available, selective inhibitor of Bcr-Abl.
  • HY-10943
    GNF-7
    		Inhibitor 98.93%
    GNF-7 is a multikinase inhibitor.
  • HY-15666A
    Olverembatinib dimesylate
    		Inhibitor 99.81%
    Olverembatinib (GZD824) dimesylate is a potent and orally active pan-Bcr-Abl inhibitor.
  • HY-111872
    SNIPER(ABL)-020
    		Inhibitor 99.44%
    SNIPER(ABL)-020, conjugating Dasatinib (ABL inhibitor) to Bestatin (IAP ligand) with a linker, induces the reduction of BCR-ABL protein.
  • HY-125834
    GMB-475
    		Inhibitor 98.98%
    GMB-475 is a degrader of BCR-ABL1 tyrosine kinase based on PROTAC, overcoming BCR-ABL1-dependent drug resistance.